Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05558111
Recruiting Observational

The Supraspinal Control of Lower Urinary Tract Function in Patients With Orthotopic Sigmoid Neobladder.

NCT05558111 · tracked via the Priya Life Science China tracker
Sponsor
Zhujiang Hospital
Phase
Observational
Started
2022-06-01
Last updated
2026-10-08

Condition(s) studied

Orthotopic Neobladder

Study summary

Orthotopic sigmoid neobladder surgery is one of the ideal urinary diversion methods after radical cystectomy.In recent years, functional imaging studies have revealed brain regions related to urinary system function, but brain activity of lower urinary tract function in neobladder patients is still unclear.The aim of this study is to explore the brain activity of urination intention and self-controlled urination behavior in patients with orthotopic sigmoid neobladder by task-state functional magnetic resonance imaging (fMRI).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Being right-handed; 2. 3 months or more after operation; 3. No contraindications to fMIR examination; 4. Voluntarily sign informed consent. Exclusion Criteria: 1. History of bladder radiotherapy; 2. History of prostate cancer; 3. Suffering from diseases affecting abdominal pressure; 4. History of abnormal brain anatomy, craniocerebral surgery, craniocerebral tumor, and craniocerebral radiotherapy; 5. History of mental disorders, Parkinson's disease, Alzheimer's disease, epilepsy, cerebral infarction, cerebral hemorrhage; 6. Claustrophobia or carrying metal implants that are not suitable for fMRI examination; 7. Diseases affecting lower urinary tract function (such as spinal cord injury, diabetic peripheral neuropathy, etc.); 8. Urethral stricture; 9. Refusing to sign the informed consent form for clinical projects; 10. Other conditions that were not suitable for inclusion according to the investigator's judgment.

Primary outcome measure(s)

  • The location of brain functional activation areas — 3 months
    Areas of the brain where excitation or inhibition occurs in fMRI images
  • The peak T-value size of the activation region — 3 months
    Peak T values of activated or inhibited regions of the brain in fMRI images

Trial sites (1)

FacilityCityRegionStatus
Zhujiang Hospital of Southern Medical University Guangzhou Guangdong Recruiting

More Zhujiang Hospital trials in China

Validation of the Accuracy of a Novel POCT Dry Electrolyte Analysis System in the Acute Care Setting Recruiting
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS Starting soon
Hemodynamic Study of In-Stent Stenosis(I) After Flow Diverter(F) Based on 3D-DSA(D) Combined With TCCD(T) Recruiting
Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia Starting soon
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05558111 on ClinicalTrials.gov ↗ ← All trials in China